BiotechTube

PRT543

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Advanced Solid Tumors

Conditions

Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia

Trial Timeline

Feb 11, 2019 → Nov 16, 2022

NCT ID
NCT03886831

About PRT543

PRT543 is a phase 1 stage product being developed by Prelude Therapeutics for Relapsed/Refractory Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT03886831. Target conditions include Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia.

What happened to similar drugs?

0 of 10 similar drugs in Relapsed/Refractory Advanced Solid Tumors were approved

Approved (0) Terminated (1) Active (9)
🔄Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
❌Blinatumomab + Standard of Care ChemotherapyAmgenPhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide + Rituximab + Doxorubicin + Vincristine + Prednisone + BendamustineGilead SciencesPhase 3
🔄Odronextamab + Lenalidomide + RituximabRegeneron PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03886831Phase 1Completed

Competing Products

20 competing products in Relapsed/Refractory Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-2416ModernaPhase 2
0
agenT-797MiNK TherapeuticsPhase 1
19
Valemetostat TosylateDaiichi SankyoPhase 2
39
Eribulin mesylateEisaiPhase 2
35
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
47
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + EpcoritamabEli LillyPhase 1/2
36
ISB 1342Glenmark PharmaceuticalsPhase 1
29
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
47
Linperlisib ； RituximabJiangsu Hengrui MedicinePhase 1/2
39
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
42
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
40
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
21
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
29
Venetoclax + DexamethasoneAbbViePhase 1/2
32
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
AZD4573AstraZenecaPhase 2
35
Moxetumomab PasudotoxAstraZenecaPre-clinical
26